Joseph Thome
Stock Analyst at TD Cowen
(0.32)
# 4,007
Out of 4,820 analysts
20
Total ratings
25%
Success rate
-29.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $13.49 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $291.38 | +37.28% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $10.50 | - | 1 | Jul 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $2.68 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $27.84 | +22.13% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $1.68 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.74 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $49.53 | -39.43% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $4.07 | - | 1 | Jan 5, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $37.53 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.64 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.13 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $106.27 | +22.33% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.31 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.84 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.33 | - | 1 | Jul 15, 2021 |
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $13.49
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $291.38
Upside: +37.28%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $10.50
Upside: -
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.68
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $27.84
Upside: +22.13%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $1.68
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.74
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $49.53
Upside: -39.43%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.07
Upside: -
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $37.53
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.64
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $5.13
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $106.27
Upside: +22.33%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.31
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.84
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.33
Upside: -